Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries.

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why it matters: Millions of Americans with acute and chronic pain are ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Washington — Federal officials on Thursday ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' pill, Journavx, for short-term pain that often follows surgery ...

Sold by Vertex Pharmaceuticals in 50-milligram tablets as Journavx, suzetrigine is the first nonopioid painkiller to target pain-signaling pathways in the peripheral nervous system before those ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks. The American ...

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The company reported a modest beat in Q4 and in-line ...

WASHINGTON (AP ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries. It’s the first ...

WASHINGTON (AP ... The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new ...